Bionomics is a global, clinical-stage biotechnology company specializing in the development of novel, first-in-class ion channel modulators aimed at treating serious central nervous system (CNS) disorders. Leveraging deep expertise in ion channel biology and translational medicine, Bionomics designs best-in-class oral, small molecules to modulate ion channel function, influence neurotransmission, and consequently downstream signaling in the brain. Their lead asset, BNC210, is a small molecule with unique properties and a highly differentiated emerging profile, offering non-sedating, non-habit forming, and non-cognition impairing anxiolytic and antidepressant effects. Currently, BNC210 is in late-stage development for the treatment of Social Anxiety Disorder (Phase 3) and Post-Traumatic Stress Disorder (Phase 3 start-up phase).